Both MPO and LIGHT are associated with increased cardiovascular disease risk and in particular sCD163 is associated with both incidence and death from cardiovascular disease [37–41], and thus reduced levels of these could be one of the mechanisms contributing to the cardioprotective effects of liraglutide. This evidence concerns the gene TNFSF14 and cardiovascular disorder.